Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Wiendl

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Medizinische Klinik, Intensivmedizin Und Notfallmedizin|June 17, 2026
[The Freiburg concept of the "Neurological Emergency Receiving Team (NERT)" : Concept for structuring of time-critical courses of action for patients with a predominant disability problem with an interdisciplinary and interprofessional emergency team in the nontraumatological resuscitation room]J Brich, M Hieber, S Petrik, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 24, 2010
Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in childrenP H Lalive, M G Häusler, H Maurey, et al.
European Journal of Neurology|January 20, 2019
Immunophenotyping of cerebrospinal fluid cells in ischaemic strokeA Schulte-Mecklenbeck, I Kleffner, C Beuker, et al.
Neurology|March 24, 2004
Rasmussen encephalitis with active inflammation and delayed seizures onsetI Korn-Lubetzki, C G Bien, J Bauer, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|November 22, 2015
Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID)P S Rommer, T Dörner, K Freivogel, et al.
Neurology|February 4, 2012
Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus controlN Schwab, J C Ulzheimer, R J Fox, et al.
Multiple Sclerosis and Related Disorders|February 26, 2022
Factors associated with treatment escalation among MS specialists and general neurologists: Results from an International cojoint studyG Saposnik, S Andhavarapu, Ó Fernández, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 25, 2012
Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapyA Harrer, H Tumani, S Niendorf, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 11, 2014
Limbic encephalitis due to GABAB and AMPA receptor antibodies: a case seriesM Dogan Onugoren, D Deuretzbacher, C A Haensch, et al.
Der Nervenarzt|August 14, 2015
[Current aspects of therapy conversion for multiple sclerosis]P Kolber, F Luessi, S G Meuth, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Medizinische Klinik, Intensivmedizin Und Notfallmedizin|June 17, 2026
[The Freiburg concept of the "Neurological Emergency Receiving Team (NERT)" : Concept for structuring of time-critical courses of action for patients with a predominant disability problem with an interdisciplinary and interprofessional emergency team in the nontraumatological resuscitation room]J Brich, M Hieber, S Petrik, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 24, 2010
Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in childrenP H Lalive, M G Häusler, H Maurey, et al.
European Journal of Neurology|January 20, 2019
Immunophenotyping of cerebrospinal fluid cells in ischaemic strokeA Schulte-Mecklenbeck, I Kleffner, C Beuker, et al.
Neurology|March 24, 2004
Rasmussen encephalitis with active inflammation and delayed seizures onsetI Korn-Lubetzki, C G Bien, J Bauer, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|November 22, 2015
Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID)P S Rommer, T Dörner, K Freivogel, et al.
Neurology|February 4, 2012
Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus controlN Schwab, J C Ulzheimer, R J Fox, et al.
Multiple Sclerosis and Related Disorders|February 26, 2022
Factors associated with treatment escalation among MS specialists and general neurologists: Results from an International cojoint studyG Saposnik, S Andhavarapu, Ó Fernández, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 25, 2012
Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapyA Harrer, H Tumani, S Niendorf, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 11, 2014
Limbic encephalitis due to GABAB and AMPA receptor antibodies: a case seriesM Dogan Onugoren, D Deuretzbacher, C A Haensch, et al.
Der Nervenarzt|August 14, 2015
[Current aspects of therapy conversion for multiple sclerosis]P Kolber, F Luessi, S G Meuth, et al.
Pageof 8